White label ELPA - ClinicalTrials.eu

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Not recruiting

2 1
Investigated Drugs:
- Zasocitinib
+7
Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

Not recruiting

3 1
Investigated Diseases:
- Endocrine ophthalmopathy
Investigated Drugs:
- Batoclimab
Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Not recruiting

3 1 1 1
Investigated Drugs:
- Ustekinumab
- Guselkumab
+1
Study of Axatilimab for Patients with Chronic Graft Versus Host Disease After Two Prior Treatments

Not recruiting

2 1 1
Investigated Diseases:
- Chronic graft versus host disease
Investigated Drugs:
- Axatilimab
Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Not recruiting

3 1
Investigated Diseases:
- Hepatic cirrhosis
Investigated Drugs:
- Resmetirom
Study on the Safety of ARV-471 and Everolimus for Patients with Advanced or Metastatic ER+, HER2- Breast Cancer

Not recruiting

1 1 1 1
Investigated Drugs:
Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

Not recruiting

2 1 1
Investigated Drugs:
- Degarelix
+1
Study on ANV600 and Pembrolizumab for Patients with Advanced Solid Tumors

Not recruiting

2 1 1 1
Investigated Diseases:
- Neoplasm
Investigated Drugs:
- Anv600
- Pembrolizumab
Study Comparing Alectinib and Crizotinib for Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Anaplastic lymphoma kinase gene mutation
Investigated Drugs:
Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
- Non-small cell lung cancer metastatic
Investigated Drugs:
+2

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies